Aileron Therapeutics Interest Expense 2011-2026 | ALRN

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Aileron Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
48 K	685 K	544 K	318 K	441 K	-661 K	587 K	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
685 K	-661 K	280 K

Quarterly Interest Expense Aileron Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-89 K	49 K	108 K	-	224 K	97 K	92 K	-	156 K	205 K	232 K	-	4 K	-	-22 K	-	66 K	304 K	-	-738 K	5 K	10 K	62 K	112 K	166 K	208 K	101 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
304 K	-738 K	64.4 K

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
Aligos Therapeutics ALGS	2.2 M	$ 8.74	0.23 %	$ 86.4 M	USA
Allakos ALLK	8 K	-	-	$ 28.6 M	USA
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.62	-1.09 %	$ 8.71 B	Australia
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
BioNTech SE BNTX	14.2 M	$ 98.41	1.77 %	$ 27.2 B	Germany
Cabaletta Bio CABA	2 M	$ 3.26	1.87 %	$ 328 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
AlloVir ALVR	1.44 M	-	4.14 %	$ 49.1 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Genfit SA GNFT	4.68 M	-	2.54 %	$ 160 B	France
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
bluebird bio BLUE	16.4 M	-	-	$ 546 M	USA
Amphastar Pharmaceuticals AMPH	23 K	$ 21.38	0.09 %	$ 999 M	USA
Checkpoint Therapeutics CKPT	344 K	-	-	$ 169 M	USA
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
AgeX Therapeutics AGE	51 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Akebia Therapeutics AKBA	58 K	$ 1.56	6.12 %	$ 401 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.05	4.45 %	$ 5.02 M	Israel
Aquestive Therapeutics AQST	6.55 M	$ 4.15	-0.95 %	$ 444 M	USA
Arcutis Biotherapeutics ARQT	443 K	$ 25.09	4.02 %	$ 3.19 B	USA
Chimerix CMRX	11 M	-	-	$ 756 M	USA
Concert Pharmaceuticals CNCE	-309 K	-	-	$ 401 M	USA
AIkido Pharma AIKI	-5.79 M	-	1.93 %	$ 17.4 M	USA
Celldex Therapeutics CLDX	927 K	$ 33.33	2.27 %	$ 2.21 B	USA
Autolus Therapeutics plc AUTL	36.7 M	$ 1.48	0.68 %	$ 394 M	Britain
Cidara Therapeutics CDTX	5.81 M	-	-	$ 1.41 B	USA
Forte Biosciences FBRX	-396 K	$ 32.42	5.95 %	$ 420 M	USA
CNS Pharmaceuticals CNSP	7.03 K	$ 2.64	8.42 %	$ 1.17 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
CTI BioPharma Corp. CTIC	13.1 M	-	-	$ 1.2 B	USA